On November 11, local time, Pfizer and Blackstone Life Sciences announced that they had reached a strategic co-funding agreement. According to the agreement, funds managed by Blackstone Life Sciences will cover up to 1.5 billion US dollars in research and development costs for a monthly weight loss injection drug being tested by Pfizer until 2028. In exchange, Blackstone will be eligible for payments tied to US regulatory approvals and specific sales milestones. Pfizer will retain full operational control and decision-making power over the project.

Zhitongcaijing · 2d ago
On November 11, local time, Pfizer and Blackstone Life Sciences announced that they had reached a strategic co-funding agreement. According to the agreement, funds managed by Blackstone Life Sciences will cover up to 1.5 billion US dollars in research and development costs for a monthly weight loss injection drug being tested by Pfizer until 2028. In exchange, Blackstone will be eligible for payments tied to US regulatory approvals and specific sales milestones. Pfizer will retain full operational control and decision-making power over the project.